Izervay, which is the brand name for avacincaptad pegol, received FDA approval on August 4, 2023.

Vaccinex Announces Promising Results from SIGNAL-AD Phase 1b/2 Trial of Pepinemab for Alzheimer's Disease.

Zuranolone, marketed under the brand name Zurzuvae, is approved by the FDA for the treatment of postpartum depression (PPD) in adults.

Myeloid Therapeutics begins administering MT-303, a new RNA CAR targeting GPC3, in a Phase 1 trial for late-stage hepatocellular carcinoma (HCC).

Lotilaner ophthalmic, marketed under the brand name Xdemvy, has been approved by the FDA for the treatment of Demodex blepharitis.

SanBio Gains Approval for "AKUUGO® Suspension for Intracranial Use" (INN: Vandefitemcel) to Treat Persistent Motor Paralysis from Traumatic Brain Injuries.

Donislecel, branded as Lantidra, was approved by the FDA on June 28, 2023. It represents a significant development in the treatment of type 1 diabetes.

The combination therapy was well tolerated, and the safety profile of BNT111 with cemiplimab was consistent with previous trials of BNT111 with anti-PD-(L)1-based treatments.

Rozanolixizumab, marketed under the brand name Rystiggo, was approved by the FDA on June 26, 2023.

Tectonic Therapeutic has announced that the U.S. Food and Drug Administration has approved its Investigational New Drug application for TX45.

Ritlecitinib, marketed under the brand name Litfulo, received FDA approval on June 23, 2023, specifically for the treatment of severe alopecia areata.

FibroGen Releases Main Outcomes from Two Advanced Pamrevlumab Pancreatic Cancer Trials and Shares Corporate News.